Microport Cardioflow Medtech Corp
Microport Cardioflow Medtech Corp develops and commercializes medical devices for cardiovascular and other therapeutic applications, primarily in the Asia-Pacific region.
Business. Microport Cardioflow Medtech Corp (2160.HK) is a healthcare services and equipment company operating in the medical equipment, supplies, and distribution industry. The firm generates revenue through the sale of medical products, including capital equipment and consumables. It is listed on the Hong Kong Stock Exchange. Specific details regarding operating segments and geographic presence are not provided.
Analyst recommendations
2 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Microport Cardioflow Medtech Corp (2160.HK) is a healthcare services and equipment company operating in the medical equipment, supplies, and distribution industry. The firm generates revenue through the sale of medical products, including capital equipment and consumables. It is listed on the Hong Kong Stock Exchange. Specific details regarding operating segments and geographic presence are not provided.
Microport Cardioflow Medtech Corp has a fully diluted share count of 1,273,311,439, with no difference between basic and diluted shares outstanding, indicating no dilution risk from stock options or convertible instruments. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.
Profitability and return metrics are not available in the valuation snapshot, and no industry_config preferred metrics are provided for comparison. This limits the ability to assess the company's performance relative to its peers in the medical equipment and supplies sector.
The company's geographic exposure is concentrated in the Asia-Pacific region, as disclosed in its business operations, but no specific revenue concentration by segment or geography is provided in the available data. This lack of detail makes it difficult to evaluate the diversification of its revenue streams.
Growth trajectory is not quantified in the outlook, and no numeric deltas are provided for the current or next fiscal year. Analysts have issued a mean price target of 6.20 USD, with a mean recommendation of 1.50 (leaning toward "strong buy"), but no revenue growth estimates are available to support this.
Risk factors include the inability to assess liquidity risk due to missing balance-sheet data. The company is also flagged for potential dilution risk, though it is currently rated as low. No dilution sources are explicitly cited in the source documents, and no adjustments are applied in the custom valuations.
Recent events, including filings or transcripts, are not detailed in the available data. Analysts have issued a uniform price target of 6.20 USD, with one "strong buy" and one "buy" recommendation, but no recent earnings calls or regulatory updates are referenced.
- The company has no dilution risk from stock options or convertible instruments, as basic and diluted shares are equal.
- Analysts have issued a strong buy recommendation with a consistent price target of 6.20 USD.
- Liquidity risk could not be assessed due to missing balance-sheet data.
- Revenue concentration and segment performance details are not disclosed in the available data.
- No growth estimates are provided for the current or next fiscal year.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Revenue $57.0M, +12,3% YoY; Operating income −438,3% YoY.
- ▍Revenue $57.0M, +12,3% YoY
- ▍Operating income −438,3% YoY
- ▍Net income −170,8% YoY
- ▍Net margin -33.0%
Revenue $50.8M, +7,0% YoY; Operating income +104,9% YoY.
- ▍Revenue $50.8M, +7,0% YoY
- ▍Operating income +104,9% YoY
- ▍Net income +89,6% YoY
- ▍Free cash flow +71,5% YoY
- ▍Net margin -13.7%
Revenue $47.5M, +27,3% YoY; Operating income +0,3% YoY.
- ▍Revenue $47.5M, +27,3% YoY
- ▍Operating income +0,3% YoY
- ▍Net income +1,4% YoY
- ▍Free cash flow +4,3% YoY
- ▍Net margin -140.2%
Revenue $37.3M, +19,8% YoY; Operating income −126,7% YoY.
- ▍Revenue $37.3M, +19,8% YoY
- ▍Operating income −126,7% YoY
- ▍Net income −137,7% YoY
- ▍Free cash flow −64,9% YoY
- ▍Net margin -181.0%
Revenue $31.1M; Operating income -$24.7M.
- ▍Revenue $31.1M
- ▍Operating income -$24.7M
- ▍Net margin -91.3%
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -0,01 |
| Revenue | —no estimate | —no estimate | 300,1M USD |
| Operating income | —no estimate | —no estimate | 17,8M USD |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Microport Cardioflow Medtech Corp Market data — financials · 2026-05-26
- Microport Cardioflow Medtech Corp Market data — analyst estimates · 2026-05-26